)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Immunome
Immunome (IMNM) investor relations material
Immunome Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026
Pipeline strategy and focus
Pipeline centers on targeted oncology therapies, emphasizing cell surface and small molecule approaches, excluding cell therapy and CAR-T.
Rigorous diligence process led to in-licensing of promising assets, with a focus on robust data and manufacturing capabilities.
Infrastructure supports both antibody-based and small molecule drugs, enabling flexibility in pipeline expansion.
Desmoid tumor program and commercial outlook
Gamma secretase inhibitor showed strong phase III results in desmoid tumors, with positive outcomes across all key endpoints.
U.S. prevalence estimated at 11,000 patients seeking therapy annually, with a potential market exceeding 3,000 patients for blockbuster status.
NDA submission targeted within months, with a record hazard ratio of 0.16 indicating high efficacy.
Physicians value once-daily dosing, superior compliance, and pain relief compared to competitors.
Medical affairs team expansion aims to support physician engagement and optimize real-world use.
Competitive positioning and launch plans
Varegacestat offers higher objective response rates and once-daily dosing versus Ogsiveo, addressing compliance and pain management.
Market entry strategy focuses on new and prevalent patients not responding to current therapies.
Emphasis on medical affairs and post-approval studies to address physician needs and expand indications.
NDA submission expected within four to six months of data readout, leveraging experienced regulatory and clinical teams.
Varegacestat: How to displace Ogsiveo patients?
ADC 3.0: Clinical impact of efflux pump resistance?
Varegacestat: Path to 3,000 patients for $1B market?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Immunome earnings date
Q4 202517 Mar, 2026
Immunome
Next Immunome earnings date
Q4 202517 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Immunome, Inc. is a biotechnology company focused on developing targeted cancer therapies. The company leverages a proprietary discovery platform to identify novel antigens and develop corresponding therapies, particularly in the field of oncology. Immunome's product pipeline includes several candidates, such as AL102, a gamma secretase inhibitor currently in Phase 3 trials for the treatment of desmoid tumors, and other preclinical assets aimed at targeting specific cancer markers through various therapeutic approaches, including antibody-drug conjugates (ADCs) and radioligand therapies. The company is headquartered in Bothell, Washington, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage